Patiromer clinical trials
Also written Veltassa and RLY5016.
How each study uses patiromer is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the patiromer studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 Oct 2015 · VELTASSA · NDA 205739 (FDA, Drugs@FDA)
- European Union
- 19 Jul 2017 · Veltassa · EMEA/H/C/004180 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2017 (4)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 12
Relypsa, Inc. (7) · Vifor Pharma, Inc. (3) · Mario Negri Institute for Pharmacological Research (2) · Vifor Fresenius Medical Care Renal Pharma (1) · Duke University (1) · Wake Forest University Health Sciences (1) · Dominic Raj (1) · Oslo University Hospital (1)
Often tested with
Tested in the same studies.
Polyethylene glycol 3350 (1) · Polystyrene sulfonic acid (1) · Sodium zirconium cyclosilicate (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test patiromer.
- Dec 2026Potassium Correction for RAAS Optimization in Chronic Kidney DiseasePhase 4 · University Medical Center Groningen
Studies
Open first, then newest update. How each study uses patiromer is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 25
- Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium LevelsRecruitingPhase 2Vifor Pharma, Inc.NCT05766839Written as PatiromerHow we know
- Potassium Correction for RAAS Optimization in Chronic Kidney DiseaseRecruitingPhase 4University Medical Center GroningenNCT06256991Written as Patiromer 8400 MG [Veltassa]How we know
- Patiromer and Diet/hrQoL in Chronic DialysisRecruitingPhase 3Mario Negri Institute for Pharmacological ResearchNCT06858280Written as Patiromer 8400 MG [Veltassa]How we know
- Comparison of Potassium Binders in the ERTerminatedPhase 4University of California, IrvineNCT04585542Written as PatiromerHow we know
- Trial Evaluating the Efficacy and Safety of Patiromer in Chinese SubjectsCompletedPhase 3Vifor Fresenius Medical Care Renal PharmaNCT05136664Written as Patiromer Powder for Oral Suspension (Part A)How we know
- Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease PatientsCompletedPhase 4Duke UniversityNCT03781089Written as Patiromer Oral Powder ProductHow we know
- RELieving Increasing oEdema Due to Heart FailureTerminatedPhase 4NHS Greater Glasgow and ClydeNCT04142788Written as PatiromerHow we know
- Patiromer Trial in CKD Stage IIIB to VTerminatedPhase 3Mario Negri Institute for Pharmacological ResearchNCT05786469Written as Veltassa Oral Powder ProductHow we know
- Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia ManagementTerminatedPhase 4Comprehensive Research AssociatesNCT04443608Written as Patiromer Powder for Oral Suspension [Veltassa]How we know
- A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney DiseaseCompletedPhase 3Wake Forest University Health SciencesNCT03740048Written as Patiromer Oral ProductHow we know
- The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With HyperkalemiaCompletedPhase 2Dominic RajNCT03326583Written as PatiromerHow we know
- Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant RecipientsCompletedPhase 4Oslo University HospitalNCT05029310Written as Patiromer Oral ProductHow we know
- Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)CompletedPhase 3Vifor Pharma, Inc.NCT03888066Written as PatiromerHow we know
- Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and HyperkalemiaTerminatedPhase 2Vifor Pharma, Inc.NCT03087058Written as PatiromerHow we know
- Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.CompletedPhase 4NYU Langone HealthNCT03183778Written as PatiromerHow we know
- A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)CompletedPhase 3Relypsa, Inc.NCT01810939Written as PatiromerHow we know
- Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)CompletedPhase 2Relypsa, Inc.NCT01371747Written as patiromerHow we know
- Evaluation of Patiromer in Heart Failure PatientsCompletedPhase 2Relypsa, Inc.NCT00868439Written as patiromerHow we know
- Patiromer With or Without Food for the Treatment of HyperkalemiaCompletedPhase 4Relypsa, Inc.NCT02694744Written as patiromerHow we know
- Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney DiseaseCompletedPhase 2Relypsa, Inc.NCT03071263Written as PatiromerHow we know
Codes
What other systems call patiromer · ClinicalTrials.gg INT005946
- MeSH (NLM) C568789patiromerOne source NLM
- UNII (FDA) 1FQ2RY5YHHPATIROMERConfirmed FDA, NLM, Wikidata
- RxNorm 1716203Confirmed FDA, Wikidata
- Wikidata Q21284261patiromerConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166500PatiromerOne source FDA
- DrugBank DB09263One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C568789 | patiromer | One source NLM |
| UNII (FDA) | 1FQ2RY5YHH | PATIROMER | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1716203 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21284261 | patiromer | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166500 | Patiromer | One source FDA |
| DrugBank | DB09263 | — | One source Wikidata |
Also registered as patiromer calcium (UNII 7T97I3787N) and patiromer sorbitex calcium (UNII 0LB9J2797D · RxNorm 2204723).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.